Utility of next generation sequencing for differentiating malignant PEComa from metastatic melanoma

Affiliations

• ¹ Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia; NSW Health Pathology, Sydney, NSW, Australia; Royal Prince Alfred Hospital, Sydney, NSW, Australia.
• ² Douglass Hanly Moir Pathology, Sonic Healthcare, Macquarie Park, NSW, Australia; Department of Clinical Medicine, Faculty of Medicine and Health Sciences, Macquarie University, Sydney, NSW, Australia.
• ³ Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia; Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia; Royal North Shore and Mater Hospitals, Sydney, New South Wales, Australia; Faculty of Medicine and Health, The University of Sydney, NSW, Australia.
• ⁴ Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia; Royal North Shore and Mater Hospitals, Sydney, New South Wales, Australia; Faculty of Medicine and Health, The University of Sydney, NSW, Australia.
• ⁵ Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia; Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia; Faculty of Medicine and Health, The University of Sydney, NSW, Australia.
• ⁶ Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia; NSW Health Pathology, Sydney, NSW, Australia; Royal Prince Alfred Hospital, Sydney, NSW, Australia; Charles Perkins Centre, The University of Sydney, Sydney, NSW, Australia; Faculty of Medicine and Health, The University of Sydney, NSW, Australia. Electronic address: richard.scolyer@health.nsw.gov.au.